Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy

Leukemia

Volumn 28, Issue 3, 2014, Pages 577-588

  Stankov, M V ^a   El Khatib, M ^a   Kumar Thakur, B ^a   Heitmann, K ^a   Panayotova Dimitrova, D ^b   Schoening, J ^a   Bourquin, J P ^c   Schweitzer, N ^a   Leverkus, M ^b   Welte, K ^a   Reinhardt, D ^a   Li, Z ^d   Orkin, S H ^e,f,g   Behrens, G M N ^a   Klusmann, J H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Division of Pediatric Oncology Universitä ts Kinderklinik Zurich   (Switzerland)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

AML; ATG7; Autophagy; Down syndrome; HDAC inhibitor

Indexed keywords

APICIDIN; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PANOBINOSTAT; REACTIVE OXYGEN METABOLITE; RESVERATROL; SURAMIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYSOSOME; MITOCHONDRION; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID; MICE; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895791148     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.264     Document Type: Article

References (56)

1. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008; 111: 2991-2998.
2. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355-1360.
3. O'Brien MM, Cao X, Pounds S, Dahl GV, Raimondi SC, Lacayo NJ et al. Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: A report from the AML02 multicenter trial and the Children's Oncology Group study POG 9421. Leukemia 2013; 27: 731-734.
4. Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev 2010; 24: 1659-1672.
5. Blink M, Buitenkamp TD, van den Heuvel-Eibrink MM, Danen-van Oorschot AA, de Haas V, Reinhardt D et al. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 2011; 25: 1365-1368.
6. Klusmann JH, Reinhardt D, Hasle H, Kaspers GJ, Creutzig U, Hahlen K et al. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia 2007; 21: 1584-1587.
7. Barbetti V, Gozzini A, Cheloni G, Marzi I, Fabiani E, Santini V et al. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics 2013; 8: 210-219.
8. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
9. Ungewickell A, Medeiros BC. Novel agents in acute myeloid leukemia. Int J Hematol 2012; 96: 178-185.
10. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321-1330.
11. Trus MR, Yang L, Suarez SF, Bordeleau L, Jurisica I, Minden MD. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005; 19: 1161-1168.
12. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009; 32: 591-601.
13. Garcia-Manero G. Can we improve outcomes in patients with acute myelogenous leukemia?. incorporating HDAC inhibitors into front-line therapy. Best Pract Res Clin Haematol 2012; 25: 427-435.
14. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226-235.
15. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005; 12: 482-491.
16. McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, Gausdal G et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 2012; 26: 910-917.
17. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12: 9-14.
18. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76.
19. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 2011; 471: 74-79.
20. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007; 110: 313-322.
21. Carew JS, Medina EC, Esquivel JA, Mahalingam D, Swords R, Kelly K et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010; 14: 2448-2459.
22. Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci USA 2012; 109: 6561-6565.
23. Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 2010; 24: 478-490.
24. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31-36.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
26. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
27. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 2006; 103: 3339-3344.
28. Tonelli R, Sartini R, Fronza R, Freccero F, Franzoni M, Dongiovanni D et al. G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia 2006; 20: 1307-1310.
29. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007; 21: 574-576.
30. Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004; 18: 1207-1214.
31. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008; 22: 1026-1034.
32. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature 2010; 466: 68-76.
33. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140: 313-326.
34. Mizushima N. Autophagy: Process and function. Genes Dev 2007; 21: 2861-2873.
35. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA 2008; 105: 3374-3379.
36. Lee IH, Finkel T. Regulation of autophagy by the p300 acetyltransferase. J Biol Chem 2009; 284: 6322-6328.
37. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.
38. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010; 6: 322-329.
39. Chan LL, Shen D, Wilkinson AR, Patton W, Lai N, Chan E et al. A novel image-based cytometry method for autophagy detection in living cells. Autophagy 2012; 8: 1371-1382.
40. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12: 222-230.
41. Zhang Y, Qi H, Taylor R, Xu W, Liu LF, Jin S. The role of autophagy in mitochondria maintenance: Characterization of mitochondrial functions in autophagy-deficient S. cerevisiae strains. Autophagy 2007; 3: 337-346.
42. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12: 401-410.
43. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-213.
44. Aronson LI, Davenport EL, Mirabella F, Morgan GJ, Davies FE. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application. Leukemia 2013; 27: 2397-2403.
45. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-Type AML. Leukemia 2008; 22: 1728-1736.
46. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
47. Maiso P, Colado E, Ocio EM, Garayoa M, Martin J, Atadja P et al. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia 2009; 23: 2265-2274.
48. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004; 65: 571-581.
49. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 673-678.
50. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009; 280: 192-200.
51. Fullgrabe J, Lynch-Day MA, Heldring N, Li W, Struijk RB, Ma Q et al. The histone H4 lysine 16 acetyltransferase hMOF regulates the outcome of autophagy. Nature 2013; 500: 468-471.
52. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 2010; 22: 132-139.
53. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-967.
54. Oehme I, Linke JP, Bock BC, Milde T, Lodrini M, Hartenstein B et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci USA 2013; 110: E2592-E2601.
55. Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA 2011; 108: 4123-4128.
56. Moresi V, Carrer M, Grueter CE, Rifki OF, Shelton JM, Richardson JA et al. Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice. Proc Natl Acad Sci USA 2012; 109: 1649-1654..